Data-driven analysis backed by 1,900++ verified biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
The median upfront for a Phase 2 anti-VEGF ophthalmology licensing deal has hit $280M — a number that would have been unthinkable five years ago. Here's exactly how these deals are structured, what the comparable transactions reveal, and where the smart money is negotiating harder.
The median upfront for a Phase 2 GLP-1 agonist infectious disease licensing deal now sits at $280M — a number that would have been unthinkable for this intersection two years ago. Here's what the benchmark data, five real comparable deals, and a new valuation framework tell BD teams and founders about where this market is heading.
The median upfront for an ASO hematology licensing deal at Phase 2 now sits at $281.1M — a number that would have been unthinkable three years ago. Here's what's driving the inflation, how the biggest comparable deals were structured, and what BD teams and founders should demand at the table.
The median upfront for a Phase 2 radiopharmaceutical rare disease licensing deal has hit $281.1M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct the comparable deals, and deliver a tactical negotiation playbook for both biotech founders and pharma BD teams.
The median upfront for a peptide cardiovascular licensing deal at Phase 2 has hit $120M, with total deal values stretching past $2B. We deconstructed five major 2024-2025 transactions to show exactly how these deals are structured — and where the leverage actually sits.
The median upfront payment for a Phase 2 CAR-T (hematologic) metabolic licensing deal now sits at $281.1M — a figure that would have been unthinkable three years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver a tactical negotiation playbook for both sides of the table.
The median upfront for a Phase 2 PROTAC immunology licensing deal has hit $281.1M — a number that would have been unthinkable three years ago. We deconstruct the benchmark data, analyze five major 2025 comparables, and lay out a negotiation playbook for both biotech founders and pharma BD teams.
The median upfront for an mRNA neurology licensing deal at Phase 2 is $120M — but the real story is in the milestone architecture. We deconstruct the biggest neurology deals of 2024–2025 and introduce the Neuro-Platform Conviction Ratio to separate signal from noise in term sheets.
The median upfront payment for an RNAi oncology licensing deal at Phase 2 is now $296M — a number that would have been unthinkable three years ago. Here's the full benchmark data, deal deconstructions, and a negotiation playbook built for the people actually sitting across the table.
The median upfront for a Phase 2 bispecific antibody women's health licensing deal now sits at $120M — a figure that would have been unthinkable for this therapeutic area three years ago. Here's what's driving the premiums, how the biggest recent deals were structured, and what your term sheet should look like.
The median upfront payment for a Phase 2 ADC gastroenterology licensing deal has hit $296M — a number that would have been unthinkable three years ago. We break down the benchmarks, deconstruct the biggest comparable deals, and give you a negotiation playbook grounded in verified data.
The median upfront payment for an anti-VEGF dermatology licensing deal at Phase 2 has hit $296M — a number that would have been unthinkable five years ago. Here's what's driving those valuations, how the biggest deals were structured, and what both founders and BD teams should demand at the table.
The median upfront payment for a Phase 2 GLP-1 agonist ophthalmology licensing deal has hit $296M — a number that would have been unthinkable three years ago. Here's how the deal structures actually break down, what the comparable transactions reveal about buyer conviction, and what both founders and BD teams should demand at the table.
The median upfront for a Phase 2 ASO infectious disease licensing deal now sits at $296M — a number that would have been unthinkable five years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver a tactical negotiation playbook for both founders and BD professionals.
The median upfront for a Phase 2 radiopharmaceutical hematology licensing deal has hit $296M — a number that would have been unthinkable three years ago. Here's how the deal structures break down, what the comparable transactions reveal about buyer conviction, and exactly where the negotiation leverage sits today.
The median upfront for a Phase 2 peptide rare disease licensing deal now sits at $296M — a number that would have been unthinkable five years ago. We break down the benchmark data, deconstruct the comparable deals driving these valuations, and deliver a tactical playbook for both licensors and licensees navigating this market.
The median upfront payment for a Phase 2 CAR-T (hematologic) cardiovascular licensing deal now sits at $296M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct five major comparable deals, and lay out the negotiation playbook for both founders and BD teams.
The median upfront for Phase 2 PROTAC metabolic licensing deals hit $296M in 2024-2025, with total deal values stretching to $3.4B. Here's what's driving the premium valuations and how to structure these deals.
Phase 2 mRNA immunology licensing deals now command a median $296M upfront — but the real story is in how Big Pharma structures these milestone-heavy bets. Here's what the latest deal data reveals about valuation gaps and negotiation leverage.
The median upfront for Phase 2 RNAi neurology licensing deals has reached $296M — a figure that reflects both the validated potential of RNA interference in neurological disorders and the desperation of Big Pharma to secure differentiated CNS assets. Here's what the premium pricing actually buys you.
The median upfront payment for Phase 2 cell therapy oncology licensing deals has reached $296M — a figure that reflects both the transformative potential and clinical risk inherent in these assets. Here's what the data reveals about deal structures and negotiation leverage.
The median upfront for Phase 2 ADC women's health licensing deals has hit $296M — triple the figure from pre-2020. The billion-dollar question: are buyers overpaying for unproven assets or correctly pricing the next generation of targeted therapeutics?
The median upfront for Phase 2 anti-VEGF gastroenterology licensing deals has reached $296M — a figure that reflects the critical inflection point where Big Pharma bets on inflammatory bowel disease franchises. Here's how these deals are actually structured and why the upfront is only half the story.
The median upfront for a Phase 2 GLP-1 agonist dermatology licensing deal is now $120M — triple the figure from traditional dermatology assets. The convergence of metabolic and inflammatory pathways is reshaping deal valuations across the sector.
The median upfront for Phase 2 ASO ophthalmology licensing deals has reached $296M — a figure that reflects both the modality's precision potential and Big Pharma's desperation for retinal disease assets. Here's what the benchmark data reveals about current deal structures and where the market is heading.
Phase 2 radiopharmaceutical infectious disease licensing deals are commanding unprecedented upfront payments, with a median of $296M — nearly triple traditional small molecule levels. The convergence of precision targeting and infectious disease urgency is reshaping deal economics.
Phase 2 peptide hematology licensing deals now command a median $296M upfront with total deal values reaching $3.4B. The premium reflects Big Pharma's hunger for differentiated blood disorder assets, but the deal structures reveal surprising patterns about risk allocation and buyer conviction.
Phase 2 CAR-T licensing deals in hematologic rare diseases are hitting $296M median upfronts—nearly triple the figure from three years ago. The gap between upfront and total deal value reveals where Big Pharma is placing its biggest bets.
Phase 2 PROTAC cardiovascular licensing deals now command a median $296M upfront — reflecting Big Pharma's aggressive pursuit of protein degradation platforms. The total deal values tell an even more striking story about cardiovascular risk premium.
The median upfront for Phase 2 mRNA metabolic licensing deals hit $120M in 2025 — a figure that would have been inconceivable five years ago. Here's what BD teams and founders need to know about structuring deals in today's market.
Regeneron paid Telix $40M to enter radiopharma — 1% of what BMS paid for RayzeBio. A structural breakdown of why the deal signals the end of radiopharma's M&A era, and what comes next for the eight big pharmas still without a radiopharma presence.
The median upfront for Phase 2 RNAi immunology licensing deals has reached $245M — a figure that reflects both the maturity of RNA interference platforms and Big Pharma's conviction in immune-targeted therapies. But the real story lies in how these deals are structured.
The median upfront for Phase 2 cell therapy neurology licensing deals has hit $245M — driven by Big Pharma's desperate hunt for differentiated CNS assets. Here's what separates winning deal structures from value-destroying ones.
Phase 2 gene therapy oncology licensing deals now command $245M median upfronts with total values reaching $2.5B. The recent BioNTech-BMS $1.5B upfront deal signals a fundamental shift in risk pricing.
Phase 2 anti-VEGF women's health licensing deals now command a median upfront of $245M, with total deal values reaching $2.5B. Here's what BD teams need to know about structuring these high-stakes transactions.
The median upfront for Phase 2 GLP-1 agonist gastroenterology licensing deals has hit $245M — a staggering figure that reflects Big Pharma's aggressive pursuit of next-generation metabolic assets. Yet the most striking deals show $0M upfronts with multi-billion total values, signaling a fundamental shift in how these deals get structured.
Phase 2 ASO dermatology licensing deals command a median $245M upfront—but the real story is in the milestone structures. Here's how Big Pharma is valuing skin-deep innovation.
Phase 2 radiopharmaceutical ophthalmology licensing deals now command median upfronts of $120M with total values reaching $2.5B. The precision targeting capability of radiopharmaceuticals in ocular diseases is driving unprecedented valuations that fundamentally challenge traditional ophthalmology deal economics.
The median upfront for Phase 2 peptide infectious disease licensing deals hit $245M in 2024, with total deal values reaching $2.5B. These structures reflect unprecedented Big Pharma urgency around antimicrobial resistance and pandemic preparedness.
The median upfront for Phase 2 CAR-T hematologic licensing deals has hit $245M — a figure that reflects both the transformative potential and commercial complexity of cellular therapies. Here's what BD teams and founders need to know about structuring these deals in today's market.
Phase 2 PROTAC rare disease licensing deals now command median upfronts of $245M—nearly double the industry average. The structures reveal why Big Pharma is betting billions on protein degradation platforms.
Phase 2 mRNA cardiovascular licensing deals command a median $245M upfront — nearly triple the biotech sector average. The premium reflects Big Pharma's desperation to capture the next wave of genetic medicines before patent cliffs hit.
The median upfront for Phase 2 RNAi metabolic licensing deals has reached $245M — reflecting Big Pharma's aggressive pursuit of validated RNA interference platforms in obesity and diabetes. Here's what the benchmark data reveals about deal structures and negotiation leverage.
The median upfront for Phase 2 cell therapy immunology licensing deals has reached $245M, with total deal values ranging up to $2.5B. Here's what the latest benchmark data reveals about deal structures and negotiation dynamics.
The median upfront for Phase 2 gene therapy neurology licensing deals is now $120M — more than triple the oncology benchmark. Here's why neurological assets command premium valuations and what BD teams are paying for when they structure these $2.5B deals.
The median upfront for Phase 2 monoclonal antibody oncology licensing deals has reached $245M — but the real story is in the total deal values exceeding $2.5B. Here's what the data reveals about today's market dynamics.
The median upfront for Phase 2 GLP-1 agonist women's health licensing deals has reached $245M, with total deal values exceeding $2.5B. Here's what's driving these unprecedented valuations and how to structure your next deal.
Phase 2 ASO gastroenterology licensing deals are commanding median upfronts of $245M—nearly double the industry average across therapeutic areas. The modality premium is real, but the deal structures reveal surprising patterns about Big Pharma's risk tolerance in GI.
The median upfront for Phase 2 radiopharmaceutical dermatology licensing deals hit $245M in 2024 — a premium that reflects both the precision targeting potential and manufacturing complexity of this emerging modality.
The median upfront for Phase 2 peptide ophthalmology licensing deals has reached $245M — driven by fierce competition for differentiated eye disease assets. Here's what the benchmark data reveals about structure, pricing, and where the market heads next.
Phase 2 CAR-T hematologic infectious disease licensing deals command median upfronts of $120M with total deal values reaching $2.5B. Here's what the latest deal structures reveal about market dynamics and negotiation leverage.
The median upfront for Phase 2 PROTAC hematology licensing deals hit $245M in 2024 — signaling unprecedented confidence in targeted protein degradation. Here's what's driving these valuations and how to structure your next deal.
The median upfront for Phase 2 mRNA rare disease licensing deals has reached $245M — a figure that reflects both the transformative potential of the modality and Big Pharma's desperate need for differentiated rare disease assets. Here's what the benchmark data reveals about structuring these deals.
Phase 2 RNAi cardiovascular licensing deals now command a median $245M upfront — nearly double the cross-therapeutic average. The premium reflects both modality maturation and cardiovascular's massive commercial potential.
The median upfront for Phase 2 cell therapy metabolic licensing deals has hit $245M — a figure that would have bought you an entire biotech five years ago. The premium reflects Big Pharma's metabolic platform desperation, but the deal structures reveal who's really driving value.
The median upfront for Phase 2 gene therapy immunology licensing deals hit $120M in 2025 — reflecting unprecedented buyer conviction in cellular reprogramming platforms. Here's what BD teams need to know about structuring these complex transactions.
Phase 2 gene therapy immunology licensing deals now command median upfronts of $245M—triple the levels from three years ago. Here's what's driving the premium and how to structure these complex transactions.
The median upfront for Phase 2 monoclonal antibody neurology licensing deals hit $245M in 2024-2025, with total deal values reaching $2.5B. But the zero-upfront acquisition trend is reshaping how these deals get structured.
The median upfront for Phase 2 small molecule oncology licensing deals has reached $245M — driven by platform premiums and patent cliff pressures. Here's how the biggest players are structuring these billion-dollar bets.
Phase 2 ASO women's health licensing deals command median upfronts of $245M with total values exceeding $1.2B. The milestone-heavy structures reveal buyer uncertainty about regulatory pathways in reproductive health.
The median upfront for Phase 2 radiopharmaceutical gastroenterology licensing deals has reached $245M — a figure that reflects both the sector's therapeutic promise and the infrastructure complexity these assets demand.
The median upfront for a Phase 2 peptide dermatology licensing deal hit $245M in 2024 — reflecting Big Pharma's aggressive pursuit of differentiated assets in a crowded field. Here's what the latest deal structures reveal about valuations, risk allocation, and negotiation leverage.
The median upfront for a Phase 2 CAR-T hematologic ophthalmology licensing deal is now $120M — a figure that reflects the convergence of two premium therapeutic areas. Here's what the data reveals about these complex transactions.
PROTAC infectious disease licensing deals at Phase 2 command a median $245M upfront — nearly triple the industry average for traditional small molecules. The structures reveal a fundamental shift in how Big Pharma values degrader platforms.
The median upfront for Phase 2 mRNA hematology licensing deals hit $245M in 2024—but zero-upfront structures dominate the biggest transactions. Here's what BD teams and founders need to know about this counterintuitive market.
The median upfront for Phase 2 RNAi rare disease licensing deals hit $245M in 2024 — nearly triple the figure from five years ago. Here's what's driving these valuations and how to structure deals that actually make sense.
The median upfront payment for Phase 2 cell therapy cardiovascular licensing deals has reached $245M — a figure that would have bought an entire biotech company five years ago. Here's why Big Pharma is paying these astronomical premiums and what it means for your next negotiation.
Phase 2 gene therapy metabolic licensing deals now command a median upfront of $245M — nearly triple the figure from three years ago. The surge reflects Big Pharma's desperation to secure next-generation metabolic assets before competitors.
The median upfront for Phase 2 monoclonal antibody immunology licensing deals has hit $120M — a figure that would have been considered astronomical just five years ago. But with Blueprint commanding $9.5B from Sanofi and Nimbus securing $4B from Takeda, the market has fundamentally repriced risk at the Phase 2 inflection point.
Gilead's $465M option/license deal with Tubulis signals a disciplined re-entry into the ADC space after Trodelvy setbacks. We break down the deal economics, rNPV framework, and what the structure reveals about large pharma ADC strategy in 2026.
Over $40B in biopharma partnership value was terminated in 2024 alone. We analyze the top terminations, the pattern of serial deal dissolutions, and how this trend is reshaping out-licensing strategy and deal structure negotiations.
Neurocrine's $2.9B all-cash acquisition of Soleno Therapeutics adds VYKAT XR — the first approved treatment for Prader-Willi Syndrome hyperphagia — to a growing rare disease portfolio. We model the deal economics, assess the acquisition premium, and benchmark against rare disease M&A history.
Oncology remains the dominant therapeutic area for biopharma M&A, with ADCs driving the largest transactions. This comprehensive benchmarking report analyzes deal structures across clinical stages, models returns under uncertainty, and identifies which pharma companies still need ADC franchises.
The median upfront for small molecule neurology licensing deals at Phase 2 is $257M — but recent blockbusters like J&J-Intra-Cellular and BMS-Karuna reveal why total deal value matters more than headlines suggest.
The median upfront for Phase 2 bispecific antibody oncology licensing deals hit $257M in 2025 — with some deals reaching $1.5B upfront. The data reveals why Big Pharma is betting massive sums on this next-generation modality.
Phase 2 radiopharmaceutical licensing deals in women's health now command a median upfront of $257M — reflecting the market's conviction that targeted therapies will reshape gynecologic oncology and reproductive health.
The median upfront for Phase 2 peptide gastroenterology licensing deals has reached $257M, with total deal values stretching to $2.6B. Here's what's driving these valuations and how to structure your next deal.
Phase 2 CAR-T hematologic dermatology licensing deals are hitting $257M median upfronts with total values reaching $2.6B. The data reveals a market where buyers are paying platform premiums for next-generation immunotherapies.
The median upfront for Phase 2 PROTAC ophthalmology licensing deals hit $120M in 2024 — a premium that reflects both the modality's promise and Big Pharma's desperation for innovative eye disease treatments.
The median upfront for Phase 2 mRNA infectious disease licensing deals hit $257M in 2024 — reflecting unprecedented Big Pharma appetite for pandemic-ready platforms. Here's how the biggest deals were structured and what it means for your next negotiation.
Phase 2 RNAi hematology licensing deals are commanding unprecedented valuations, with median upfront payments hitting $257M and total deal values soaring past $2.6B. The data reveals why Big Pharma is betting massive sums on blood disorder therapeutics.
The median upfront for Phase 2 cell therapy rare disease licensing deals has reached $257M — reflecting unprecedented buyer conviction in next-generation therapeutics. Here's what BD professionals and founders need to know about structuring these deals.
Phase 2 gene therapy cardiovascular licensing deals now command a median upfront of $257M — reflecting the premium buyers pay for platform technologies in a therapeutic area where gene therapy is finally showing clinical proof-of-concept. Here's what the recent Novartis and Roche deals reveal about current market dynamics.
The median upfront for Phase 2 monoclonal antibody metabolic licensing deals hit $257M in 2024-2025 — a figure that reflects Big Pharma's desperate hunt for metabolic assets amid the GLP-1 revolution. Here's what BD teams need to know about deal structures that now routinely exceed $2B in total value.
The median upfront for Phase 2 small molecule immunology licensing deals hit $257M in 2025 — driven by Big Pharma's scramble for immune-oncology assets. But the real story is in the milestone structures that reveal buyer conviction.
The median upfront for Phase 2 bispecific antibody neurology licensing deals has hit $120M, with total deal values reaching $2.5B. Here's what's driving the premium and how to structure these deals.
ADC oncology option deals at Phase 2 command median upfront payments of $120M and total deal values reaching $2.5B. Our comprehensive analysis reveals key negotiation benchmarks and recent mega-deals driving valuations.
Phase 2 ADC oncology co-development deals command median upfronts of $120M with total deal values reaching $2.5B. Recent mega-deals from BioNTech/BMS and Hengrui/GSK showcase the premium valuations driving this hot sector.
Phase 2 ADC oncology acquisitions command median upfront payments of $120M and total deal values up to $2.5B. Recent mega-deals from GSK, Pfizer, and BMS are reshaping valuation expectations for biotech founders.
Phase 2 ADC oncology licensing deals command median upfront payments of $120M with total deal values reaching $2.5B. Recent megadeals from Hengrui/GSK and BioNTech/BMS are reshaping valuation expectations.
Drawing from thousands of disclosed biopharma deals, we distill seven negotiation strategies that consistently produce better licensing terms for biotech companies.
Phase 2 biotech assets consistently command 2-4x the deal values of Phase 1 programs. We explain the mechanics behind the phase transition premium and how to use it in negotiations.
The obesity drug market has transformed biopharma deal-making. From dual incretins to oral GLP-1 formulations, we analyze how the metabolic deal landscape is evolving in 2026.
ADC licensing deals have reached unprecedented valuations in 2026. We break down the forces behind this surge and what it means for deal teams negotiating their next partnership.
Antibody-drug conjugates are commanding significant premiums over traditional monoclonal antibodies in licensing deals. Our analysis reveals key valuation differences and emerging deal structure trends shaping the biotech landscape.
CAR-T licensing deals command significant upfront payments ranging from $5-50M for preclinical assets to $500M+ for late-stage programs. Understanding these benchmarks is crucial for successful deal structuring.
Understanding fair royalty rates is crucial for successful biotech licensing. This guide covers typical ranges, key factors, and negotiation strategies for both licensors and licensees.
The US biotech licensing landscape is experiencing unprecedented transformation in 2025, driven by AI integration, novel modalities, and evolving partnership models. This comprehensive analysis examines market dynamics, competitive positioning, and strategic opportunities shaping the industry's future.
Gene therapy and cell therapy licensing deals are commanding premium valuations in 2024, with distinct patterns emerging in deal structures and strategic priorities. Our analysis reveals key differences in risk profiles and commercial terms driving these advanced therapeutic partnerships.
Understanding phase 2 vs phase 3 biotech deal valuations differences is crucial for licensing negotiations. Phase 3 assets command significantly higher valuations due to reduced risk and proximity to market approval.
Valuing preclinical biotech assets requires balancing high uncertainty with significant potential. This guide covers practical valuation methods, market benchmarks, and key factors that drive licensing deal terms.
Navigate complex oncology licensing deals with confidence. This comprehensive guide covers structure fundamentals, market benchmarks, and critical factors that determine deal success.
Bispecific antibodies and CAR-T therapies are commanding premium licensing deals with distinct economic profiles. Our analysis reveals key valuation differences driving strategic partnerships.
Big pharma and mid-size pharmaceutical companies approach licensing deals with distinctly different strategies and preferences. Understanding these differences is crucial for successful partnerships and deal-making in today's competitive biotech landscape.
China's biotech sector is rapidly expanding its global footprint through strategic outbound licensing deals. This analysis examines key trends, competitive dynamics, and emerging opportunities shaping the market in 2024.
FDA breakthrough therapy designation can dramatically increase licensing deal valuations, often boosting upfront payments and milestones by 30-100%. Understanding this impact is crucial for biotech professionals structuring partnerships.
First-in-class assets are commanding significant valuation premiums over best-in-class competitors in biotech licensing deals. Our analysis reveals how market positioning, competitive dynamics, and emerging modalities are reshaping deal structures and upfront payments.
Rare disease orphan drug licensing deals are commanding unprecedented premiums in 2024, with Phase 2 assets securing $100-250M upfronts. Hot modalities like radiopharmaceuticals are driving 50-60% valuation premiums amid intense big pharma competition.
Commercial milestone structures are critical components of biotech licensing agreements that align partner incentives with market success. Understanding these payment mechanisms helps professionals negotiate better deals and manage risk effectively.
PROTAC degrader technology is commanding unprecedented valuations in pharma licensing deals, with upfront payments reaching $500M+ for early-stage assets. Major pharma companies are aggressively pursuing these protein degradation platforms amid patent cliffs and pipeline gaps.
Small molecule drug licensing has reached new valuation heights in 2025, with Phase 2 ADC assets commanding $100-250M upfronts. Radiopharmaceuticals are trading at 50-60% premiums while geopolitical factors create regional pricing disparities.
CAR-T cell therapy licensing deals are commanding premium valuations in 2025, with solid tumor CAR-T assets and next-generation platforms driving unprecedented deal activity. Big pharma's aggressive pursuit of differentiated cell therapy platforms is reshaping market dynamics.
Gene therapy licensing deals command premium valuations despite manufacturing challenges. Phase 2 deals range from $60-250M upfront with total values reaching $2.5B.
Bispecific antibody licensing deals are reshaping pharma partnerships, with innovative platforms commanding premium valuations. Our analysis reveals the key trends driving this $15B+ market.
Understanding biotech valuation methods for early stage assets is crucial for successful licensing negotiations. This guide covers key approaches, market benchmarks, and common pitfalls to help biotech professionals make informed valuation decisions.
Navigate biotech licensing deals with confidence. Learn essential deal structure best practices, from payment terms to milestone design, with real-world examples and market benchmarks.
Upfront payments are critical components of biotech licensing deals that can make or break partnerships. Learn how these payments work, typical ranges, and key negotiation factors.
Navigate biotech licensing deals with confidence using this comprehensive biotech term sheet key terms guide. Learn essential terminology, typical deal structures, and negotiation best practices.
Strategic decisions between licensing and acquisition can make or break a biotech partnership. Understanding when to choose each approach is critical for maximizing value and minimizing risk in pharma deals.
Radiopharmaceuticals command unprecedented licensing premiums in 2025, with Phase 2 deals averaging $120M upfront and total values reaching $2.5B. The RayzeBio acquisition reset market expectations across the hottest biotech category.
Learn proven strategies for negotiating successful biotech licensing deals. This comprehensive guide covers market benchmarks, key terms, and common mistakes to help licensing professionals secure favorable agreements.
Navigate biotech licensing deals with confidence. This comprehensive guide breaks down essential deal terms, typical ranges, and common pitfalls to help you structure successful partnerships.
Navigate oncology licensing deals with confidence. This comprehensive guide covers milestone payment structures, market benchmarks, and key factors that impact deal terms.
Biotech royalty rates in 2025 are hitting new highs, with premium modalities like radiopharmaceuticals commanding 50-60% premiums over traditional assets. Big pharma's loss-of-exclusivity cliff is driving aggressive licensing strategies and reshaping deal structures.
ADC licensing deals continue commanding premium valuations in 2025, with median Phase 2 upfronts reaching $120M and total deal values exceeding $2.5B. Post-Daiichi market dynamics are reshaping deal structures and competitive positioning.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,900++ verified biopharma transactions.
Try the Deal Calculator